Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)

Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension

The purpose of this study is to test whether the addition of inhaled iloprost is safe and effective in patients with idiopathic pulmonary arterial hypertension who are already being treated with the endothelin receptor antagonist bosentan.

Inclusion Criteria:

• IPAH
• > 3 months treatment with bosentan
• 6 minute walk distance 150 - 425 m

Exclusion Criteria:

• other forms of pulmonary hypertension
• severe comorbidities
• cotreatment with sildenafil or investigational drugs